Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC is a phase 3, randomised interventional study registered as NCT07052669 by Sun Yat-sen University, with a registry enrolment figure of 311 participants, started 2025-07-01 and due to reach its primary completion in 2029-06-30. Interventions recorded: Hypofractionated Radiation Therapy; Conventionally Fractionated Radiation Therapy; Concurrent Chemotherapy; concurrent chemotherapy; Consolidative immunotherapy. Conditions listed: Locally Advanced Non-Small Cell Lung Cancer. Primary outcome: Median Progression-Free Survival. Lung eligibility wording from the registry: "* Diagnosis: Patients must have locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC), with histological or cytological confirmation of the diagnosis". Sites: China. No results are recorded here; the registry entry is the source.